Cochrane Review Finds Alzheimer’s Anti-Amyloid Drugs Have Trivial Clinical Effects
A comprehensive Cochrane review analyzing data from 17 clinical trials involving over 20,000 participants concludes that anti-amyloid drugs for Alzheimer’s disease have trivial effects on cognitive decline and dementia severity. The study, which assessed seven different drugs over an 18-month period in patients with mild cognitive impairment or mild dementia, found no clinically meaningful improvements in functional ability. Furthermore, the analysis highlighted significant safety concerns, noting that these treatments caused more brain swelling and bleeding compared to placebos. While pharmaceutical companies and some regulators have hailed drugs like lecanemab and donanemab as breakthroughs, the review argues that the benefits are too small for patients or caregivers to notice. Critics of the review suggest that pooling older, ineffective drugs with newer ones skews the results, but authors maintain that all assessed drugs share the same mechanism of clearing amyloid plaques. The findings challenge the current medical consensus and raise questions about the cost-effectiveness and clinical value of widespread adoption, particularly within public health systems like the UK's NHS, which has previously hesitated to fund these expensive treatments due to limited benefits.
Wire timeline
Cochrane Review Finds Alzheimer’s Anti-Amyloid Drugs Have Trivial Clinical Effects
A comprehensive Cochrane review analyzing data from 17 clinical trials involving over 20,000 participants concludes that anti-amyloid drugs for Alzheimer’s disease have trivial effects on cognitive decline and dementia severity. The study, which assessed seven different drugs over an 18-month period in patients with mild cognitive impairment or mild dementia, found no clinically meaningful improvements in functional ability. Furthermore, the analysis highlighted significant safety concerns, noting that these treatments caused more brain swelling and bleeding compared to placebos. While pharmaceutical companies and some regulators have hailed drugs like lecanemab and donanemab as breakthroughs, the review argues that the benefits are too small for patients or caregivers to notice. Critics of the review suggest that pooling older, ineffective drugs with newer ones skews the results, but authors maintain that all assessed drugs share the same mechanism of clearing amyloid plaques. The findings challenge the current medical consensus and raise questions about the cost-effectiveness and clinical value of widespread adoption, particularly within public health systems like the UK's NHS, which has previously hesitated to fund these expensive treatments due to limited benefits.
The Guardian